MEDSIR-LED CLINICAL TRIALS UNITE SCIENTIFIC EXCELLENCE, PATIENT FOCUS AND STRATEGIC THINKING. MEDSIR MANAGEMENT MODEL ENSURES SPEED, RELIABILITY AND THE STREAMLINING OF CLINICAL DEVELOPMENT PLANS.
SMART STUDY DESIGNS FOR STRATEGIC CLINICAL TRIALS
WE STRIVE TO IMPROVE THE LIVES OF ALL PATIENTS WITH CANCER
The MEDSIR concept of providing a platform to facilitate the development of ideas into strategic clinical study protocols is becoming more diverse, incorporating not only new tumor types, but also modern and innovative trial designs such as umbrella and multi-tumor basket trials.
Working on a new clinical project with the expectation that it will help many patients is exhilarating for MEDSIR, a job well done means results that have the potential to change clinical practice. Here you will find our comprehensive project portfolio.
Please contact us for further information.
“LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS”
MEDSIR'S CLINICAL STUDIES
ABIGAIL
BREAST
Abemaciclib with endocrine therapy ± paclitaxel in aggressive ER+/HER2- advanced breast cancer
BARBICAN
BREAST
Evaluation of ipatasertib added to combination of neoadjuvant chemotherapy and atezolizumab in women with TNBC
COPÉRNICO
COVID-19
Tocilizumab with pembrolizumab for treatment of COVID-19 pneumonia in patients unresponsive to standard care
KELLY
BREAST
Pembrolizumab and eribulin for HR+/HER- metastatic breast cancer previously treated with antracyclines and taxanes
OPHELIA
BREAST
Olaparib plus Trastuzumab for HER2+, BRCA Mutated or HRD Advanced Breast Cancer
PATHFINDER
BREAST
Ipatasertib with non-taxane chemotherapy for taxane-pretreated unresectable locally advanced or metastatic TNBC
PHERGain
BREAST
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy
TRASTYVERE
BREAST
Clinical benefit of trastuzumab with lapatinib in HER2+ breast cancer previously treated with trastuzumab and/or lapatinib
BIOPER
BREAST
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer
DEBBRAH
BREAST
Trastuzumab deruxtecan in HER2+ advance breast cancer with brain mets and/or leptomeningeal carcinomatosis
LINGain
BREAST
Sub-study of predictive immunogenicity biomakers for target therapy in HER2+ early breast cancer
METALLICA
BREAST
Metformin to prevent hyperglycemia in HR+/HER- PI3KCA-mutated advanced breast cancer patients treated with alpelisib and endocrine therapy
ORPHEUS
PENIS
Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma
PECATI
THYMIC
Phase II study of the combination of Pembrolizumab and Lenvatinib in pre-treated thymic carcinoma
POEM
ENDOMETRIUM
Identification of endometrial cacinoma biomarkers associated with a short term exposure to temsirolimus
REVERT
BREAST
Eribulin monotherapy or eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy
ZZFIRST
PROSTATE
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer
ATractiB
BREAST
First-line atezolizumab with paclitaxel and bevacizumab for advanced or metastatic TNBC
BRIDGE
LUNG
Durvalumab and chemotherapy induction followed by durvalumab and radiotherapy in large volume stage III NSCLC
DxCARTES
BREAST
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB HR+, HER2- Breast Cancer
NOBROLA
BREAST
A Two-stage Simon Design Phase II Study of Single Agent Olaparib for Non-BRCA MBC Patients With HRD
PALMIRA
BREAST
Palbociclib with second-line endocrine therapy for HR+/HER2- Advanced Breast Cancer patients who had a clinical benefit during first-line palbociclib-based treatment
POLEN
ENDOMETRIUM
Biomarker changes associated to short exposure to olaparib as potential predictors in Endometrial Carcinoma
transFAL
BREAST
Sub-study of predictive biomarkers for palbociclib and endocrine therapy in ER+/HER2- advanced breast cancer
AZENT
LUNG
Osimertinib in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
EXCAAPE
PROSTATE
Evaluation of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
LUZERN
BREAST
Niraparib plus Aromatase Inhibitors for Luminal-like and gBRCA or HRD-positive Metastatic Breast Cancer
NSABP FB-7
BREAST
Neoadjuvant therapy with weekly (1) paclitaxel and neratinib, or (2) trastuzumab and paclitaxel, or (3) neratinib, trastuzumab, and paclitaxel, followed by doxorubicin and cyclophosphamide for postoperative locally...
PARSIFAL
BREAST
Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer
POLTER
BREAST
Optimization of balixafortide with nab-paclitaxel or eribulin for HER2- advanced breast cancer
THELMA
BREAST
Trastuzumab emtansine (TDM1) with non pegylated liposomal doxorubicin in HER2+ metastic breast cancer
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
YEAR
CONGRESS
ABSTRACT (Posters, presentations, etc.)
PROJECT
EXCAAPE
a multicenter, single-arm, open-label, non-controlled phase IIa clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide.
ESMO
2020
KELLY
A phase II study of pembrolizumab and eribulin in patients with HRpositive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
SABCS
2019
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).
SABCS
2019
TRANSFAL
Prospective evaluation of predictive/prognostic biomarkers for palbociclib and endocrine therapy in ER positive HER2 negative advanced metastatic breast cancer within the PARSIFAL clinical trial.
SABCS
2019
PALMIRA
PALbociclib rechallenge in horMone receptor-posItive/HER2-negative Advanced breast cancer.
ESMO
2019
Other MEDSIR related articles
